Table 1.
Distribution of demographic, clinical, and health care setting characteristics for adolescents and young adults with cancer diagnosed 2007–2008 by cancer type (n = 388*)
| Characteristic | Cancer type | |||||
|---|---|---|---|---|---|---|
| All combined |
Acute lymphoblastic leukemia | Germ cell* | Hodgkin’s lymphoma |
Non-Hodgkin’s lymphoma | Sarcoma | |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
| Total | (n = 388) | (n = 27) | (n = 69) | (n = 137) | (n = 126) | (n = 29) |
| Age at initial diagnosis, y | ||||||
| 15–19 | 58 (14.9) | 13 (48.1) | 7 (10.1) | 17 (12.4) | 11 (8.7) | 10 (34.5) |
| 20–24 | 66 (17.0) | ‡ | 16 (23.2) | 23 (16.8) | 16 (12.7) | 7 (24.1) |
| 25–29 | 97 (25.0) | 5 (18.5) | 18 (26.1) | 44 (32.1) | 24 (19.0) | 6 (20.7) |
| 30–34 | 81 (20.9) | - | 16 (23.2) | 30 (21.9) | 32 (25.4) | ‡ |
| 35–39 | 86 (22.2) | 5 (18.5) | 12 (17.4) | 23 (16.8) | 43 (34.1) | ‡ |
| Race/ethnicity | ||||||
| Non-Hispanic white | 222 (57.2) | 12 (44.4) | 40 (58.0) | 86 (62.8) | 71 (56.3) | 13 (44.8) |
| Hispanic | 77 (19.8) | 10 (37.0) | 22 (31.9) | 19 (13.9) | 21 (16.7) | 5 (17.2) |
| Non-Hispanic black | 45 (11.6) | ‡ | ‡ | 19 (13.9) | 15 (11.9) | ‡ |
| Other/unknown | 44 (11.3) | ‡ | ‡ | 13 (9.5) | 19 (15.1) | 7 (24.1) |
| Sex | ||||||
| Male | 197 (50.8) | 13 (48.1) | 50 (72.5) | 54 (39.4) | 61 (48.4) | 19 (65.5) |
| Female | 191 (49.2) | 14 (51.9) | 19 (27.5) | 83 (60.6) | 65 (51.6) | 10 (34.5) |
| Insurance source | ||||||
| Public | 70 (18.0) | 8 (29.6) | 9 (13.0) | 24 (17.5) | 22 (17.5) | 7 (24.1) |
| Private | 305 (78.6) | 19 (70.4) | 57 (82.6) | 110 (80.3) | 97 (77.0) | 22 (75.9) |
| Unknown or no insurance | 13 (3.4) | - | ‡ | ‡ | 7 (5.6) | - |
| Annual median household income in census tract at diagnosis (quartiles) | ||||||
| Q1 (<=$40K) | 98 (25.3) | 5 (18.5) | 16 (23.2) | 34 (24.8) | 36 (28.6) | 7 (24.1) |
| Q2 (>$40K - $54K) | 97 (25.0) | 8 (29.6) | 17 (24.6) | 36 (26.3) | 30 (23.8) | 6 (20.7) |
| Q3 (>$54K - $72K) | 98 (25.3) | 10 (37.0) | 21 (30.4) | 30 (21.9) | 28 (22.2) | 9 (31.0) |
| Q4 (>$72K) | 95 (24.5) | ‡ | 15 (21.7) | 37 (27.0) | 32 (25.4) | 7 (24.1) |
| Hospital (initial treatment) | ||||||
| NCI-designated cancer center | 79 (20.4) | 13 (48.1) | 9 (13.0) | 34 (24.8) | 16 (12.7) | 7 (24.1) |
| Academic institution | 50 (12.9) | ‡ | 9 (13.0) | ‡ | 29 (23.0) | 7 (24.1) |
| Cancer center, NOS | 162 (41.8) | 10 (37.0) | 28 (40.6) | 62 (45.3) | 52 (41.3) | 10 (34.5) |
| Community hospital | 79 (20.4) | ‡ | 22 (31.9) | 28 (20.4) | 26 (20.6) | ‡ |
| Unknown | 18 (4.6) | ‡ | ‡ | 10 (7.3) | ‡ | ‡ |
| Clinical trial participation† | ||||||
| No or not recorded in medical record | 339 (87.4) | 15 (55.6) | 63 (91.3) | 122 (89.1) | 120 (95.2) | 19 (65.5) |
| Yes | 49 (12.6) | 12 (44.4) | 6 (8.7) | 15 (10.9) | 6 (4.8) | 10 (34.5) |
| Pediatric oncology specialist involved in care vs medical oncologist (ages < 25 only) | ||||||
| No | 95 (76.6) | 10 (58.8) | 23 (100.0) | 31 (77.5) | 21 (77.8) | 10 (58.8) |
| Yes | 29 (23.4) | 7 (41.2) | - | 9 (22.5) | 6 (22.2) | 7 (41.2) |
| Summary stage at diagnosis | ||||||
| Local | 84 (21.6) | - | 11 (15.9) | 21 (15.3) | 43 (34.1) | 9 (31.0) |
| Regional | 141 (36.3) | - | 30 (43.5) | 71 (51.8) | 29 (23.0) | 11 (37.9) |
| Distant | 157 (40.5) | 27 (100.0) | 28 (40.6) | 42 (30.7) | 52 (41.3) | 8 (27.6) |
| Unstaged | 6 (1.5) | - | - | ‡ | ‡ | ‡ |
| Surveillance, epidemiology and end-results region | ||||||
| San Francisco Bay area | 95 (24.5) | 5 (18.5) | 22 (31.9) | 33 (24.1) | 28 (22.2) | 7 (24.1) |
| Los Angeles County | 47 (12.1) | - | 15 (21.7) | - | 25 (19.8) | 7 (24.1) |
| Greater California | 36 (9.3) | ‡ | ‡ | 13 (9.5) | 12 (9.5) | ‡ |
| Detroit Metropolitan area | 45 (11.6) | ‡ | 8 (11.6) | 21 (15.3) | 10 (7.9) | ‡ |
| Iowa | 29 (7.5) | ‡ | ‡ | 12 (8.8) | 8 (6.3) | ‡ |
| Seattle-Puget Sound area | 73 (18.8) | ‡ | 10 (14.5) | 32 (23.4) | 21 (16.7) | 6 (20.7) |
| Louisiana | 63 (16.2) | 6 (22.2) | 7 (10.1) | 26 (19.0) | 22 (17.5) | ‡ |
* From the total Adolescents and Young Adults study sample of 504 cases, we excluded 116 male germ cell (testis) cases with Tumor, Node, Metastases Stage I, T1, or T2. All 116 cases received standard primary treatment (orchiectomy and surveillance). NCI = National Cancer Institute; NOS = non-NCI designated.
† Composite derived from patient self-report and medical record review.
‡ Data not shown because of small cell size.